君实生物（01877）今日盘中大涨5.01%，引起了市场的广泛关注。
消息面上，全球肿瘤学盛会美国癌症研究协会（AACR）2026年年会于近期举行，君实生物的核心管线JS207（PD-1/VEGF）和JS212（EGFR/HER3 ADC）将在大会上披露关键临床数据。其中，JS207有望年内进入关键注册临床阶段，JS212计划年底启动关键注册临床，这些进展增强了市场对公司创新药研发前景的信心。
此外，太平洋证券发布研究报告，上调君实生物目标价至53.12元，并给予“买入”评级。该报告指出，公司核心产品特瑞普利单抗销售收入保持高速增长，公司亏损显著收窄，且在手现金充裕，同时多项核心管线具有催化剂，进一步提振了投资者情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.